Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
Key facts
- Where
- Amsterdam, NetherlandsSee the site
Where in Netherlands
- Netherlands Cancer Institute-Antoni van LeeuwenhoekAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Netherlands Cancer Institute
- Trial code
- NCT07511933
- Record updated
- 24 July 2026
- Original description
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.Read full original descriptionShow less
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Stereotactic Irradiated Brain Metastases: a Feasibility Study
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
Inclusion: For all groups:; Written informed consent; Age ≥ 18 years old; WHO PS 0-3; Measurable lesion ≥10mm according to RANO BM; For brain metastases groups:; newly diagnosed brain metastases from either NSCLC (group 1) or melanoma (group 2) or breast cancer (group 7); For radiation necrosis groups:; Brain lesion at the location of a formerly brain metastases that has been treated with SRT (> 9 months ago), with the definite diagnosis of radiation necrosis at the location of formerly SRT-treated brain metastases of NSCLC (group 3), melanoma (group 4) and/ or breast cancer (group 8); For diagnostic dilemma groups:; Brain lesion at the location of a formerly brain metastases with a diagnostic dilemma of radiation necrosis and recurrent brain metastases of NSCLC (group 5), melanoma (group 6) and/ or breast cancer (group 9).
Exclusion: Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan; Known allergy to Ga68-PSMA; For all groups:; Life expectancy less than 3 months; Patients with known prostate carcinoma; Pregnancy.